HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Clinical trial NCT05602597 · COMPLETED

Trial details

NCT number: NCT05602597
Sponsor: Hutchmed
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory Lymphoma

Start date: 2022-06-01
Primary completion: 2022-08-06
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.